Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
NCT ID: NCT00402948
Last Updated: 2012-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
10 participants
INTERVENTIONAL
2007-02-28
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TPI ASM8
ASM8 0.25mg
TPI ASM8
0.25mg, 0.5mg for 14 days, daily dosage
ASM8 as TPI ASM8
TPI ASM8 0.5mg
ASM8
inhalation 0.25mg daily for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TPI ASM8
0.25mg, 0.5mg for 14 days, daily dosage
ASM8
inhalation 0.25mg daily for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild to moderate asthmatic in general good health
* On either low-dose inhaled corticosteroid or steroid naive
* No other asthma medication
* Regular sputum producer
* EOS more than 3% at randomization,
* FEV1 \> 70%
Exclusion Criteria
* Any condition that may affect the conduct of the study as per the investigators
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Syntara
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Parameswaram Nair, MD
Role: PRINCIPAL_INVESTIGATOR
Firestone Institute for Respiratory Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Calgary COPD & Asthma Program
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, Canada
St-Paul's Hospital
Vancouver, British Columbia, Canada
McMaster University Hospital
Hamilton, Ontario, Canada
Firestone Institute for Respiratory Health
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
Institut Thoracique de Montreal
Montreal, Quebec, Canada
Hopital Sacre Coeur
Montreal, Quebec, Canada
Hopital Laval- Centre de recherche de Cardiologie et Pneumologie
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TPI ASM8 -204
Identifier Type: -
Identifier Source: org_study_id